U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 3Cl.Sm
Molecular Weight 259.281
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SAMARIUM CHLORIDE SM-153

SMILES

[Cl-].[Cl-].[Cl-].[153Sm+3]

InChI

InChIKey=BHXBZLPMVFUQBQ-LZPLZWJISA-K
InChI=1S/3ClH.Sm/h3*1H;/q;;;+3/p-3/i;;;1+3

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Sm
Molecular Weight 152.9221
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Samarium SM-153 lexidronam is a chelated complex of a radioisotope of the element samarium with ethylenediamine tetra(methylene phosphonic acid) (EDTMP). Samarium Sm-153 EDTMP has an affinity for bone and concentrates in areas of bone turnover in association with hydroxyapatite. In clinical studies employing planar imaging techniques, more Samarium (153Sm) lexidronam accumulates in osteoblastic lesions than in normal bone with a lesion-to-normal bone ratio of approximately 5. It is indicated for the relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan. It should not be given concurrently with chemotherapy or external beam radiation therapy unless the benefit outweighs the risks. The most common adverse events are: nausea and vomiting, hemoglobin decrease, myasthenia, paresthesia, thrombocytopenia and abdominal pain.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
QUADRAMET

Approved Use

QUADRAMET® is indicated for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan.

Launch Date

1997

Sample Use Guides

The recommended dose of QUADRAMET® is 1.0 mCi/kg, administered intravenously over a period of one minute through a secure in-dwelling catheter and followed with a saline flush.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:21:53 GMT 2023
Edited
by admin
on Sat Dec 16 09:21:53 GMT 2023
Record UNII
9B6QP3540H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SAMARIUM CHLORIDE SM-153
Common Name English
(153SM)SAMARIUM CHLORIDE
Common Name English
SAMARIUM-153 CHLORIDE
Common Name English
SAMARIUM-153 TRICHLORIDE
Common Name English
SAMARIUM CHLORIDE (153SMCL3)
Common Name English
Code System Code Type Description
EVMPD
SUB121468
Created by admin on Sat Dec 16 09:21:53 GMT 2023 , Edited by admin on Sat Dec 16 09:21:53 GMT 2023
PRIMARY
FDA UNII
9B6QP3540H
Created by admin on Sat Dec 16 09:21:53 GMT 2023 , Edited by admin on Sat Dec 16 09:21:53 GMT 2023
PRIMARY
CAS
36148-56-8
Created by admin on Sat Dec 16 09:21:53 GMT 2023 , Edited by admin on Sat Dec 16 09:21:53 GMT 2023
PRIMARY
SMS_ID
100000144633
Created by admin on Sat Dec 16 09:21:53 GMT 2023 , Edited by admin on Sat Dec 16 09:21:53 GMT 2023
PRIMARY
PUBCHEM
73295286
Created by admin on Sat Dec 16 09:21:53 GMT 2023 , Edited by admin on Sat Dec 16 09:21:53 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY